• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于癌症患者来源类器官模型中药物反应的多重活细胞成像

Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer.

作者信息

Colling Kaitriana E, Symons Emily L, Buroni Lorenzo, Sumanisiri Hiruni K, Andrew-Udoh Jessica, Witt Emily, Losh Haley A, Morrison Abigail M, Leslie Kimberly K, Dunnill Christopher J, De Bono Johann S, Thiel Kristina W

机构信息

Department of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

Cancer Biology Graduate Program, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

出版信息

bioRxiv. 2023 Nov 17:2023.11.15.567243. doi: 10.1101/2023.11.15.567243.

DOI:10.1101/2023.11.15.567243
PMID:38014133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10680710/
Abstract

Patient-derived organoid (PDO) models of cancer are a multifunctional research system that better recapitulates human disease as compared to cancer cell lines. PDO models can be generated by culturing patient tumor cells in extracellular basement membrane extracts (BME) and plating as three-dimensional domes. However, commercially available reagents that have been optimized for phenotypic assays in monolayer cultures often are not compatible with BME. Herein we describe a method to plate PDO models and assess drug effects using an automated live-cell imaging system. In addition, we apply fluorescent dyes that are compatible with kinetic measurements to simultaneously quantitate cell health and apoptosis. Image capture can be customized to occur at regular time intervals over several days. Users can analyze drug effects in individual Z-plane images or a Z Projection of serial images from multiple focal planes. Using masking, specific parameters of interest are calculated, such as PDO number, area, and fluorescence intensity. We provide proof-of-concept data demonstrating the effect of cytotoxic agents on cell health, apoptosis and viability. This automated kinetic imaging platform can be expanded to other phenotypic readouts to understand diverse therapeutic effects in PDO models of cancer.

摘要

癌症患者来源的类器官(PDO)模型是一种多功能研究系统,与癌细胞系相比,它能更好地模拟人类疾病。通过在细胞外基底膜提取物(BME)中培养患者肿瘤细胞并铺板成三维圆顶状,可以生成PDO模型。然而,为单层培养中的表型分析优化的市售试剂通常与BME不兼容。在此,我们描述了一种铺板PDO模型并使用自动活细胞成像系统评估药物效果的方法。此外,我们应用与动力学测量兼容的荧光染料来同时定量细胞健康状况和细胞凋亡。图像捕获可以设置为在几天内按固定时间间隔进行。用户可以在单个Z平面图像或来自多个焦平面的系列图像的Z投影中分析药物效果。使用掩膜,可以计算感兴趣的特定参数,如PDO数量、面积和荧光强度。我们提供了概念验证数据,证明了细胞毒性剂对细胞健康、细胞凋亡和活力的影响。这个自动动力学成像平台可以扩展到其他表型读数,以了解癌症PDO模型中的各种治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/6051104cd20b/nihpp-2023.11.15.567243v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/f649d79be7df/nihpp-2023.11.15.567243v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/e8fcc8459ff4/nihpp-2023.11.15.567243v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/6699734d512e/nihpp-2023.11.15.567243v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/368c8c999fea/nihpp-2023.11.15.567243v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/83b4e7f24e4a/nihpp-2023.11.15.567243v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/6051104cd20b/nihpp-2023.11.15.567243v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/f649d79be7df/nihpp-2023.11.15.567243v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/e8fcc8459ff4/nihpp-2023.11.15.567243v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/6699734d512e/nihpp-2023.11.15.567243v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/368c8c999fea/nihpp-2023.11.15.567243v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/83b4e7f24e4a/nihpp-2023.11.15.567243v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca62/10680710/6051104cd20b/nihpp-2023.11.15.567243v1-f0006.jpg

相似文献

1
Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer.用于癌症患者来源类器官模型中药物反应的多重活细胞成像
bioRxiv. 2023 Nov 17:2023.11.15.567243. doi: 10.1101/2023.11.15.567243.
2
Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer.癌症患者来源的类器官模型中的药物反应的多重实时细胞成像。
J Vis Exp. 2024 Jan 5(203). doi: 10.3791/66072.
3
Hydrogel-based colorectal cancer organoid co-culture models.基于水凝胶的结直肠癌类器官共培养模型。
Acta Biomater. 2021 Sep 15;132:461-472. doi: 10.1016/j.actbio.2020.12.037. Epub 2020 Dec 31.
4
Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications.用于癌症药物发现应用的患者来源的肝细胞癌肿瘤类器官培养物的小型化与表征
SLAS Discov. 2025 Jan;30:100201. doi: 10.1016/j.slasd.2024.100201. Epub 2024 Dec 9.
5
Erratum: High-Throughput Identification of Resistance to Pseudomonas syringae pv. Tomato in Tomato using Seedling Flood Assay.勘误:利用幼苗浸没法高通量鉴定番茄对丁香假单胞菌 pv.番茄的抗性。
J Vis Exp. 2023 Oct 18(200). doi: 10.3791/6576.
6
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.基于患者源性膀胱癌类器官的综合药物筛选和多组学特征分析揭示了吉西他滨反应的新的分子相关性。
Eur Urol. 2024 Nov;86(5):434-444. doi: 10.1016/j.eururo.2024.05.026. Epub 2024 Aug 17.
7
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis.使用宽场活细胞成像进行多参数肿瘤类器官药物筛选以进行批量和单细胞类器官分析
J Vis Exp. 2022 Dec 23(190). doi: 10.3791/64434.
8
The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible.使用子宫内膜癌患者来源的类器官培养物进行药物敏感性测试是可行的。
Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707. doi: 10.1097/IGC.0000000000001061.
9
Assay establishment and validation of a high-throughput organoid-based drug screening platform.建立和验证高通量类器官药物筛选平台的方法。
Stem Cell Res Ther. 2022 May 26;13(1):219. doi: 10.1186/s13287-022-02902-3.
10
Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids.患者来源的头颈部、口腔和食管癌症类器官的生成和特性分析。
Curr Protoc Stem Cell Biol. 2020 Jun;53(1):e109. doi: 10.1002/cpsc.109.

本文引用的文献

1
Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids.前列腺癌类器官衍生的异种移植物中的药物测试的活力分析和高内涵活细胞成像。
Cells. 2023 May 12;12(10):1377. doi: 10.3390/cells12101377.
2
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis.使用宽场活细胞成像进行多参数肿瘤类器官药物筛选以进行批量和单细胞类器官分析
J Vis Exp. 2022 Dec 23(190). doi: 10.3791/64434.
3
OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening.
OrBITS:用于先进药物筛选的患者来源类器官的无标记和延时监测。
Cell Oncol (Dordr). 2023 Apr;46(2):299-314. doi: 10.1007/s13402-022-00750-0. Epub 2022 Dec 12.
4
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.B7-H3 作为晚期前列腺癌的治疗靶点。
Eur Urol. 2023 Mar;83(3):224-238. doi: 10.1016/j.eururo.2022.09.004. Epub 2022 Sep 13.
5
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.功能化患者来源的类器官筛选鉴定 MCLA-158 为一种治疗性 EGFR×LGR5 双特异性抗体,在上皮肿瘤中有疗效。
Nat Cancer. 2022 Apr;3(4):418-436. doi: 10.1038/s43018-022-00359-0. Epub 2022 Apr 25.
6
Gastric cancer cell death analyzed by live cell imaging of spheroids.通过球体的活细胞成像分析胃癌细胞死亡。
Sci Rep. 2022 Jan 27;12(1):1488. doi: 10.1038/s41598-022-05426-1.
7
Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer.阻断自噬可克服妇科癌症对双组蛋白去乙酰化酶和蛋白酶体抑制的耐药性。
Cell Death Dis. 2022 Jan 17;13(1):59. doi: 10.1038/s41419-022-04508-2.
8
HER3 Is an Actionable Target in Advanced Prostate Cancer.HER3 是晚期前列腺癌的一个可操作靶点。
Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 9.
9
Organoids in image-based phenotypic chemical screens.基于图像的表型化学筛选中的类器官。
Exp Mol Med. 2021 Oct;53(10):1495-1502. doi: 10.1038/s12276-021-00641-8. Epub 2021 Oct 18.
10
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy.酪氨酸激酶抗血管生成药物西地尼布相较于贝伐单抗的优势:细胞周期阻滞及与化疗的协同作用
Pharmaceuticals (Basel). 2021 Jul 16;14(7):682. doi: 10.3390/ph14070682.